1 SB 200646A, N-(1-methyl-5-indolyl)-N'-(3-pyridyl) urea hydrochloride, the first reported selective 5-HT2C,2B over 5-HT2A receptor antagonist, (pK, rat 5-HT2c receptor 6.9, pA2 rat 5-HT2B receptor 7.5, pK, rat 5-HT2A receptor 5.2) dose-dependently blocked a putative rat model of 5-HT2c receptor activation; 1-(3-chlorophenyl)piperazine (mCPP, 5 mg kg-', i.p. 20 min pretest)-induced hypolocomotion (estimated ID50 19.2mg kg-', p.o.). 2 SB 200646A also blocked another putative in vivo model of 5-HT2c receptor function; mCPP (5 mg kg-', i.p. 20 min pretest)-induced hypophagia in 23 h food-deprived rats (estimated ID5o 18.3 mg kg-', p.o.). 3 SB 200646A did not antagonize 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head shakes in rats at doses up to 200mgkg'1, p.o., an effect thought to be mediated by 5-HT2A receptors for which SB 200646A has its next highest affinity (50 fold less) after the 5-HT2c and 5-HT2B sites.
Introduction
The 5-HTc receptor was first characterized by Pazos et al. (1984) . However, it is now recognised as belonging to the 5-HT2 receptor family on the basis of marked amino acid sequence homology (Pritchett et al., 1988; Saltzman et al., 1991) , and has therefore been renamed as the 5-HT2c receptor site (Humphrey et al., 1993) . The receptor is reported to act through the phosphoinositide hydrolysis secondary messenger system (Conn et al., 1986) and is widely distributed in both rat (Pazos & Palacios, 1985) and human (Pazos et al., 1987) brain, with particularly high density in the choroid plexus (Pazos & Palacios 1985; Pazos et al., 1987) . In rats, several in vivo responses to the putative 5-HT2c receptor agonist, 1-(3-chlorophenyl) piperazine (mCPP) have been suggested to be mediated by 5-HT2c receptor activation. These include mCPP-induced hypolocomotion (Kennett & Curzon, 1988a) , hypophagia (Kennett & Curzon, 1988b) and anxiety (Kennett et al., 1989) . mCPP-induced anxiety is of particular interest as it has been widely reported in healthy volunteers and to a greater extent in patients with either panic disorders or obsessive compulsive disorder (OCD) (see . Unfortunately mCPP is not a selective 5- HT2c receptor agonist and the pharmacological characterization of its effects in vivo result from the use of non-selective 5-HT2c receptor antagonists. In the present study we have investigated the effects of the in vivo administration of SB 200646A (N-(1-methyl-5-indolyl)-N'-(3-pyridyl) urea hydrochloride), the first reported antagonist with selectivity for the 5-HT2C over the 5-HT2A receptor (Forbes et al., 1993; Wood et al., 1993) . This compound had 50 fold selectivity for the rat 5-HT2C over the 5-HT2A receptor, and 80 fold or greater selectivity over other neurotransmitter receptors tested (Table   Author for correspondence. 1, Forbes et al., 1993) . However, SB 200646A is also equipotent at the 5-HT2B (rat stomach fundus) receptor with which the 5-HT2c receptor shares a high degree of sequence homology (Foquet et al., 1992; Kursar et al., 1992) and at which mCPP has agonist properties (Clineschmidt et al., 1985) .
Methods

Animals
Male Sprague-Dawley (CD) rats 220-250 g were housed in groups of six under a 12 h light/dark cycle (lights on 07 h 00 min) with free access to food (CRMX, Special Diet Services) and water. mCPP-induced hypolocomotion Rats were placed in a room adjacent to the experimental room on the day of the procedure. They were dosed orally 1 h pretest with SB 200646A or vehicle, and injected i.p. 20 min pretest with mCPP or saline, in groups of four. Rats were returned to their home cages after dosing. At 0 h they were each placed in automated locomotor activity cages (57 x 16.6 x 25.3 cm) made of black perspex with a clear perspex lid and sawdust-covered floor, under red light for 10 min. During this time locomotion was recorded by means of alternately breaking two photocell beams traversing opposite ends of the box 3.9 cm above floor level. mCPP-induced hypophagia Rats were individually housed on day 1 and deprived of food.
Twenty three hours later they were dosed orally with Sanger & Nelson (1989) and those for GABAA ([3H]-muscimol in rat cortex as described by Peters et al. (1988) ).
antagonist or vehicle and returned to their home cages. Forty minutes later they were given mCPP or saline i.p. and again returned to their home cages. After a further 20 min, weighed aliquots of their normal food pellets were placed in their food hoppers and the amount remaining after 2 h was measured.
Social interaction
Rats were housed singly in a room adjacent to the testing room on day 1. On day 5 they were dosed orally with SB200646A or vehicle in treatment-and weight-matched ( ± 5 g) pairs, which had not previously been housed together, and returned to their home cage. Rats were then placed in a white perspex test box (54 x 37 x 26 cm) for 15 min under bright white light (150 lux) in an adjacent darkened room containing a fan to generate white noise. Active social interaction (sniffing, following, grooming, biting, boxing and crawling over or under) was scored by a 'blind' observer by remote video monitoring and a computerised score pad. At the end of each test the box was thoroughly wiped with moistened tissue paper. Alternatively rats were individually pre-exposed to test boxes of black perspex under red light for 10 min on days 3 and 4 and tested under the same conditions on day 5.
DOI-induced head shakes
Rats were dosed orally with SB 200646A 30 min before being placed in individual clear perspex observation cages (25.4 x 25.4 x 22.2 (height) cm). Thirty minutes later 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) was given i.p. and the number of head shakes produced over the next 30 min were counted using a computerised score pad.
Drugs SB 200646A (SB) and mianserin (Organon, Newhouse, Scotland) were ground into 1% methyl cellulose in 0.9% NaCl with a drop of BRIJ 35 (Sigma Chemical Co., Poole, Dorset) dispersant using a mortar and pestle and given orally as a suspension in a 2 ml kg-' injection volume 1 h pretest. SB 200646A was neutralised to pH 4.5. SB 200646A controls were given 1% methyl cellulose in 0.9% NaCl and a drop of BRIJ 35 acidified to pH 4.5 with HCL. DOI (Research Biochemcials Inc, Natick, Massachusetts, U.S.A.) and mCPP (Sigma Chemical Co., Poole, Dorset) were dissolved in saline and given i.p. in ml kg-' injection volume 1 and 20 min pretest respectively.
Statistics
The effect of SB 200646A on mCPP-induced hypolocomotion was determined by one-way ANOVA and Newman-Keuls test, and on hypophagia and anxiogenesis by two-way ANOVA and Newman-Keuls test. All other data were subjected to one-way ANOVA and Dunnett's test. Estimates of the dose producing 50% inhibition (ID~v) of mCPP-induced hypolocomotion or hypophagia were made using the iterative curve-fitting programme 'Allfit' (DeLean et al., 1978) . All data are cited as means ± s.e.mean.
Results
Effect of SB 200646A on mCPP-induced hypolocomotion SB 200646A alone at 40 mg kg-', p.o., had no effect on locomotor activity, neither did lower doses in previous experiments (data not shown) or mianserin at 4 mg kg-', p.o. (Table 2) . mCPP (5 mg Effect of SB 200646A on 'anxiogenic-like' responses to mCPP mCPP (0.5 mg kg-', i.p.) significantly reduced total interaction scores (N 1,49) = 11.5, P<0.01), but had no effect on locomotor activity (F(1,49) = 0.86, NS). SB 200646A had no effect on total interaction scores when given alone, but significantly reversed the effect of mCPP (1(2,49) = 3.36, P <0.05). SB 2006464A also caused a significant effect on locomotion (f1R2,49) = 6.07, P<0.01), but this did not result in a significant effect between vehicleand SB 200646Atreated groups, whether given mCPP or not, when analysed by the Newman-Keuls test (Figure 2 ). Significantly different from vehicle-treated group: *P<0.05; **P< 0.01 by Dunnett's test following significant 1-way ANOVA.
Effect of SB
ure 3). The drug also caused a small increase in locomotion at 20 mg kg-', p.o. but at no other dose (F(6,67) = 2.4, P <0.05) (Figure 3) . The magnitude of the increase in total interaction induced by SB 200464A was equal to that seen after chlordiazepoxide (CDP) at a dose of 5 mg kg-', p.o.
Discussion
SB 200646A is the first reported selective 5-HT2C,2B receptor antagonist and has 50 fold selectivity for the rat 5-HT2C,2B receptors over the 5-HT2A and at least 80 fold selectivity over all other neurotransmitter receptors tested (Table 1, Forbes et al., 1993; Wood et al., 1993) . The ability of the compound to reverse mCPP-induced hypolocomotion and hypophagia, putative 5-HT2c receptor-mediated behaviours (Kennett & Curzon, 1988a,b; demonstrates in vivo efficacy. Since SB 200646A has similar potency in both models it is likely that a similar mechanism of action is indeed involved and this is likely to be via blockade of the 5-HT2C site, as previously proposed, or of the recently characterized 5-HT2B site. However, given the relatively low potency of the compound in these tests it might be suggested that SB 200646A is blocking some other site, despite its 50 fold selectivity for 5-HT2C/2B receptors. The inability of SB 200646A, at much higher doses (200 mg kg-', p.o.), to antagonize 5-HT2A-medi-ated DOI-induced head shakes (Pranzatelli, 1990; Kennett & Curzon, 1991) argues against this, as after the 5-HT2C/2B site, its next highest affinity is for the 5-HT2A receptor (Table 1) . Although both mCPP-induced hypophagia and hypolocomotion appear to be mediated by the same receptor they are independent behaviours. Thus, hypophagia caused by mCPP is blocked by cyanopindolol and (-)-propranolol (Kennett & Curzon, 1988b) unlike the hypolocomotor response (Kennett & Curzon, 1988a) while intrahypothalamic trifluoromethyl phenylpiperazine (TFMPP), a closely related 5-HT2c agonist, causes only hypophagia (Hutson et al., 1988) . That SB 200646A fully reversed the hypophagic effect of mCPP but only partially reversed hypolocomotion (Tables 2 and 3) is, however, probably due to not having administered high enough doses, although it may conceivably indicate the presence of an additional mechanism.
SB 200646A also antagonized the anxiogenic-like effect of mCPP in the rat social interaction model at similar doses to those which were effective against mCPP-induced hypolocomotion and hypophagia. Thus, the anxiogenic response is also likely to be mediated by 5-HT2C/2B receptors. This is consistent with previous evidence that non-selective 5-HT2c, 2B, but not selective 5-HT2A or antagonists blocked the effect of mCPP in this paradigm (Kennett et al., 1989) . It is also consistent with antagonism of mCPP-induced anxiety in man by both the non-selective 5-HT, and 5-HT2 receptor blockers metergoline (Kalus et al., 1990; Pigott et al., 1991) and methysergide (Kalus et al., 1990) and, in particular, by the relatively selective (see 5-HT2C,2B,2A receptor antagonist, ritanserin (Seibyl et al., 1991) .
Since activation of 5-HT2C (or 5-HT2B) receptors seems to cause anxiety, their blockade might be anxiolytic if the system is activated during stress. Indeed, immobilisation stress (Shimzu et al., 1992) , tail pinch and handling (Kalen et al., 1989) and placement on the open arms of the elevated X-maze (Wright et al., 1992) have all been shown to enhance extraneuronal 5-HT in either the hypothalamus or the hippocampus. mCPP infusion into this latter region in the rat, which contains high levels of 5-HT2c receptor mRNA (Hoffman & Mezey, 1989; Molineaux et al., 1989) and receptors (Mengod et al., 1990) , has been reported to induce anxiogenic-like responses (Whitton & Curzon, 1990) . mCPP has also been reported to potentiate periaqueductal grey-induced anxiety (Beckett et al., 1992) . The anxiolytic-like response to SB 200646A in the social interaction test may therefore be caused by antagonism of these responses and is in agreement with previous findings of the anxiolytic effects of non-selective 5-HT2C,2B, but not of 5-HT2A or other receptor antagonists, in both the rat social interaction and Geller-Seifter models of anxiety (Kennett, 1992; Kennett et al., 1993) . The lack of an anxiolytic-like response in the social interaction test when SB 200646A was given alone under low light unfamiliar conditions (Figure 2) is probably due to low intrinsic levels of anxiety under these conditions (File, 1985) . As SB 200646A has low affinity for the benzodiazepine, GABAA and TBPS binding sites (Table 1) the GABA/C1complex is unlikely to be the primary site of its anxiolytic action while the presence of 5-HT2B receptors in rat brain, let alone the hippocampus is as yet unknown.
In conclusion, experiments with SB 200646A, the first selective 5-HT2C/2B receptor antagonist, indicate that the compound has in vivo activity and that 5-HT2C/2B receptors are likely to mediate the hypolocomotion, hypophagia and anxiety induced by mCPP. Furthermore, the results suggest that selective antagonists of 5-HT2C,2B receptors possess anxiolyticlike properties. These may be of clinical relevance given reports of the clinical anxiolytic efficacy of the non-selective 5-HT2C,2B receptor antagonists, mianserin (Murphy, 1978; Russell et al., 1978; Conti & Pinder, 1979; Khan et al., 1983) and ritanserin (Ceulemans et al., 1985; Bressa et al., 1987; Pangalila-Ratu et al., 1988) . However, although there is as yet no pharmacological evidence to differentiate between EFFECTS OF A 5-HT2C/2B RECEPTOR ANTAGONIST 801 5-HT2C or 5-HT2B receptor mediation of the above effect, the 5-HT2B receptor has, to date, been identified only in mouse brain at extremely low density (Loric et al., 1992) . Furthermore while mCPP is an almost full agonist on the 5-HT2C receptor functions so far examined (see it is only a weak partial agonist on the rat stomach fundus (Clineschmidt et al., 1985) . This suggests that the 5-HT2C receptor is the more likely mediator of the hypolocomotion, hypophagia and anxiety responses to mCPP. Identification of the exact functions of the 5-HT2C, 5-HT2B and indeed of the pharmacologically similar rat and porcine endothelial receptors (Glusa & Richter, 1993; Bodelson et al., 1993) , awaits the development of selective ligands.
